MiR-19a-3p: a potential biomarker for predicting cardiac risk in anderson-fabry disease

MicroRNAs(miRNAs) have been shown to suppress the onset and progression of heart disease and have recently been widely proposed as biomarkers. However, few literatures have been reported on whether they protect against Anderson-Fabry-induced myocardial damage. The aim was to explore whether miR-19a-3p could be used as a biomarker for the diagnosis and risk assessment of Anderson-Fabry disease (AFD), distinguishing AFD from healthy controls and myocardial damage caused by AFD. 60 AFD patients and an equal number of healthy controls were recruited to analyze miR-19a-3p expression. ROC analysis evaluated their diagnostic ability, and statistical analysis demonstrated the association of clinical indicators of cardiac damage with miR-19a-3p. 53.3% of AFD patients exhibited cardiac damage, with notable structural changes in cardiac characteristics. MiR-19a-3p expression level was downregulated in AFD and AFD cardiomyopathy patients and showed high diagnostic accuracy for identifying both AFD and associated cardiac injury. It negatively correlated with severity of cardiac injury. Multivariate analysis identified miR-19a-3p as a significant independent protective factor in cardiac damage in AFD. The study identified downregulated miR-19a-3p as a potent diagnostic biomarker for AFD and its associated cardiomyopathy. MiR-19a-3p was established as an independent protective factor in cardiac damage. Thus, it was proposed as a promising candidate biomarker for AFD cardiomyopathy.